SCHEMBL30165715

SCHEMBL30165715

Nc1ccc2nc3ccc(N)cc3[s+]c2c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.50
MEN1 O00255 4/20 0.50
HTT P42858 2/20 0.50
LMNA P02545 2/20 0.50
F2 P00734 1/20 0.50
CHRM2 P08172 1/20 0.50
HTR1A P08908 1/20 0.50
ADRA2A P08913 1/20 0.50
ADORA3 P0DMS8 1/20 0.50
MAOA P21397 1/20 0.50
DRD1 P21728 1/20 0.50
ACHE P22303 1/20 0.50
PTGS1 P23219 1/20 0.50
SLC6A2 P23975 1/20 0.50
SLC6A4 P31645 1/20 0.50
OPRM1 P35372 1/20 0.50
DRD3 P35462 1/20 0.50
KDR P35968 1/20 0.50
SLC6A3 Q01959 1/20 0.50
KCNH2 Q12809 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL146313 1.00 KMT2A (0.50) KMT2AMEN1HTTLMNAF2
Iodide SCHEMBL11279046 0.98 KMT2A (0.48) KMT2AMEN1HTTLMNAF2
Hydrochloric Acid SCHEMBL40555 0.98 MAPT (0.50) KMT2AMEN1HTTLMNAF2
SCHEMBL12273001 0.90 HTR3A (0.48) KMT2AMEN1HTTLMNAF2
Iodide SCHEMBL12813166 0.88 HTR3A (0.47) KMT2AMEN1HTTLMNAF2
SCHEMBL12620639 0.88 KDM4E (0.43) KMT2AMEN1HTTLMNAF2
SCHEMBL11281816 0.88 ALDH1A1 (0.44) KMT2AMEN1HTTLMNAF2
Iodide SCHEMBL12813168 0.87 HTR3A (0.46) KMT2AMEN1HTTLMNAF2
Acetic Acid SCHEMBL755555 0.85 NQO2 (0.42) KMT2AMEN1HTTLMNAF2
Acetic Acid SCHEMBL755557 0.85 CHEK1 (0.41) KMT2AMEN1HTTLMNAF2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12441694-B2 Process for the preparation of methylene blue DISHMAN CARBOGEN AMCIS LTD. (IN) 2025-10-14 US disclosed
US-20250222006-A1 METHODS OF SYNTHESIS AND/OR PURIFICATION OF DIAMINOPHENOTHIAZINIUM COMPOUNDS WISTA LABORATORIES LTD. (SG) 2025-07-10 US disclosed
CN-117209450-A Chemical synthesis method of diaminophenothiazinium compound including methyl sulfonium chloride (MTC) 维斯塔实验室有限公司 2023-12-12 CN disclosed
CN-117209450-A Chemical synthesis method of diaminophenothiazinium compound including methyl sulfonium chloride (MTC) 维斯塔实验室有限公司 2023-12-12 CN disclosed
CN-110092764-B Chemical synthesis method of diaminophenothiazinium compound including methyl sulfonium chloride (MTC) 维斯塔实验室有限公司 2023-09-15 CN disclosed
CN-110092764-B Chemical synthesis method of diaminophenothiazinium compound including methyl sulfonium chloride (MTC) 维斯塔实验室有限公司 2023-09-15 CN disclosed
US-20230138553-A1 A Process for the Preparation of Methylene Blue DISHMAN CARBOGEN AMCIS LTD. (IN) 2023-05-04 US disclosed
EP-4121757-A1 INDICATOR FILM Insignia Technologies Limited (GB) 2023-01-25 EP disclosed
EP-4110735-A1 A PROCESS FOR THE PREPARATION OF METHYLENE BLUE Dishman Carbogen Amcis Ltd. (IN) 2023-01-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250222006-A1 METHODS OF SYNTHESIS AND/OR PURIFICATION OF DIAMINOPHENOTHIAZINIUM COMPOUNDS MB, TPMT, HBB KMT2A 936/4885MEN1 330/4885HTT 567/4885
US-12441694-B2 Process for the preparation of methylene blue B2M, LMNB2, LMNA KMT2A 2037/4885MEN1 208/4885HTT 2338/4885
US-20230138553-A1 A Process for the Preparation of Methylene Blue B2M, PURB, POLM KMT2A 884/4885MEN1 2607/4885HTT 2535/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.